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Mechanism of action studies are essential to link ob-
servable effects on cells with molecular targets of
small molecules. Caligiuri and coworkers [1] describe
how yeast three-hybrid screening identified kinases
that might mediate an intriguing tumor cell-specific
antiproliferative effect.
The search for selective small-molecule inhibitors of
protein kinases has an interesting history. Despite initial
concerns that ATP-competitive inhibitors would lack
selectivity, remarkable results have been achieved with
small molecules that are able to differentiate between
kinases possessing a high degree of sequence similar-
ity (for a review, see [2]). Selectivity assessments have
been based largely on data from in vitro kinase assays,
although frequently they are supported by functional
and phenotypic data obtained using whole cells. The
number of kinases available for assay, however, has
limited the conclusions that can be drawn about individ-
ual inhibitors. The discovery that the human kinome
consists ofw518 kinases [3] has underscored the chal-
lenge of profiling kinase inhibitors, and it has become
increasingly evident that primary sequence similarity
between proteins is not the most important determinant
of inhibitor sensitivity. Recently, several approaches
have been applied to the evaluation of kinase inhibi-
tor specificity, and the results have been enlightening.
These approaches include (1) expansion of the panel
of kinases available for in vitro assay of functional activ-
ity [4, 5], (2) display cloning [6, 7], (3) affinity chromatog-
raphy [8, 9], and (4) the yeast three-hybrid approach
(Y3H) [10, 11]. The consensus from these studies is that
small-molecule kinase inhibitors are less selective than
generally has been claimed, typically inhibiting a cross-
section of kinases that in some cases are phylogeneti-
cally quite distinct. These methods are beginning to
reveal important properties of clinical kinase inhibitors,
including marketed drugs and drug candidates, as well
as important constituents of the cell biology toolbox.
In this issue of Chemistry & Biology, Caligiuri and co-
workers [1] describe the application of Y3H to mecha-
nism of action (MOA) studies of a putative Cdk inhibitor,
RGB-286147.
Y3H is an extension of Fields and Song’s two-hybrid
method [12, 13], which was developed to detect pro-
teins that associate in cells by linking their association
to transcriptional activation of a specific reporter gene,
e.g., one required for growth on histidine-deficient
media. In Y3H (Figure 1), the DNA binding (DB) and acti-
vation domains (AD) of a transcription factor are ex-
pressed separately as fusion proteins. Linking the DB
domain to a well-characterized protein (e.g., DHFR)
and the AD domain to a library of potential target
proteins then requires that assembly of the requisite
transcription factor, and therefore reporter gene acti-
vation, be mediated by a hybrid molecule (dimerizer),consisting of an anchor compound (e.g., methotrexate)
linked to a compound whose protein target may be un-
known, such as a kinase inhibitor. Kley and coworkers
have exploited this technique to develop tools for spe-
cifically probing whole proteome cDNA libraries for tar-
gets of small-molecule kinase inhibitors. In previous
work, they demonstrated the success of Y3H in identify-
ing and confirming targets of the purine-derived kinase
inhibitor purvalanol B [14]. Remarkably in both that re-
port and in the latest study [1], the only targets identified
for these small-molecule kinase inhibitors were protein
kinases.
The pyrazolopyrimidinone RGB-286147 was selected
for MOA studies based on the properties it exhibits in
cell-based assays [1]. Despite being prepared initially
as an inhibitor of Cdk1 and Cdk2, its effects on cells
are inconsistent with exclusive inhibition of these target
kinases. Of particular note is the observation that RGB-
286147 displays differential antiproliferative activity
against noncycling HCT116 human carcinoma cells
(IC50 = 51 nM) versus noncycling human fibroblasts
(IC50 > 1 mM), which are not transformed and there-
fore more akin to nontumor (‘‘normal’’) cells. In con-
trast, RGB-286147 is similarly antiproliferative toward
HCT116 cells and human fibroblast cells when they
are actively cycling.
A Y3H screen using a dimerizer of methotrexate
connected via a PEG linker to RGB-286147 identified
several targets for this small molecule [1]. All of the pro-
teins identified and confirmed as targets, save one, are
CDK or CDK-related kinases, illustrating a remarkably
narrow spectrum of inhibitory activity. The important
confirmatory studies using yeast clones specifically ex-
pressing kinase or kinase domain proteins, or employ-
ing a related PEG-tethered pyrazolopyrimidinone as
an affinity probe, expanded the set of potential target
kinases to 14. Inhibitory potencies for eight of these
kinases were measured to validate the selection and
demonstrate functional binding.
This study identifies a relatively small number of po-
tential protein targets for RGB-286147, one or more of
which may mediate its antiproliferative effect on non-
cycling HCT116 cells [1]. Once a complete set of inhibi-
tion data is available, it would be interesting to know
whether any of the potential targets of RGB-286147
are differentially expressed in the sensitive HCT116
cells. Further sleuthing has the potential to pinpoint
a new molecular target for therapeutic intervention with
small molecules that could be effective against non-
cycling cells in a tumor mass. It may be possible to exploit
this target to increase the chances of tumor eradication
using chemotherapy.
More generally, the work by Caligiuri and coworkers
illustrates the value of proteome-wide target screening
to mechanistic studies of compounds that may not per-
form as originally intended but that still display an inter-
esting profile in cells [15, 16]. Thus, the identification of
molecules that affect cells in a specific and desirable
way followed by the application of chemical genet-
ics tools such as Y3H to identify a cross-section of
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ate a fingerprint against which future molecules may be
compared. One can envisage the optimization of kinase
inhibitors for activity against a specific subset of kinase
targets or a particular signaling pathway that has been
associated with the biological effect of interest. Impor-
tantly, these affinity-based techniques are not limited
to compounds that bind to an enzyme active site, but
in principle could be extended to allosteric inhibitors
and inhibitors of proteins that lack a catalytic function.
Affinity chromatography and Y3H are complemen-
tary, since each is subject to different limitations includ-
ing the use of cell lysate versus intact live cells, the use
of mammalian versus yeast cells, and very likely differ-
ent influences attributable to protein expression levels.
Both techniques are limited by the requirement to mod-
ify chemically or to immobilize the biologically active
probe molecule. Y3H shares an advantage with display
cloning, namely that identification of the target protein is
linked to identification of the corresponding gene, facil-
itating its identification and subsequent protein over-
expression. The visual read-out from Y3H (cell growth),
and its potential for automation at many steps, offers
considerable potential for parallel screens against dif-
ferent proteomes, multiple protein classes, or mutants
of the same protein. The selection of compounds match-
Figure 1. Schematic of a Yeast Three-Hybrid System
Transcription factor DNA binding (BD, dark blue) and activation
(AD, light blue) domains are fused to DHFR (red) and an expressed
library of proteins (green), respectively. A library of chemical dimer-
izers comprised of methotrexate (black) and a candidate small mol-
ecule (yellow) joined by a linker has the potential to bind to both
DHFR and the unknown, target protein. Binding reconstitutes the
transcription factor activity leading to expression from a reporter
gene promoter (gray) and an observable phenotype. Figure pro-
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Small Molecules
Driving Myotube Fission
In this issue of Chemistry & Biology, Duckmanton
et al. [1] have rigorously studied myotube fragmenta-
tion, or ‘‘cellularization,’’ triggered by microtubule-ing a specific binding profile from a library of
potential inhibitors also is conceivable. The future ex-
tension of three-hybrid technology to mammalian cells
will expand the scope of compounds that can be used,
increase the potential for competition assays, as well
as provide a more direct relationship to phenotypic data
from mammalian cells. As such powerful tools become
increasingly available, it no longer will be sufficient to fo-
cus on a small number of proteins in evaluating inhibitor
selectivity. Chemical tools will have to meet a higher
standard of characterization, and we all may have to
be more circumspect in our use of the word ‘‘selective.’’
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disrupting agents. They convincingly demonstrate
that cellularization remains integral to myogenic de-
differentiation, but is insufficient for reentry of the
mononucleate progeny into the cell cycle.
For decades, researchers have examined in great
detail the mechanisms underlying the spontaneous
